ADmit Therapeutics

Logo ADmit Therapeutics

Contact information

ADmit Therapeutic S.L.
Marta Barrachina
Calle Feixa Llarga (Edifici Consorci Biopol), s/n, Oficina 3
L'Hospitalet de Llobregat
Barcelona
605121564
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biomarkers
      • In vitro diagnostics
    • Therapeutic areas
      • Central nervous system
  • D. Services
    • R&D services
      • Bioinformatics
      • Genomics
Commissions

ADmit Therapeutics, S.L. is a company spin-off from Bellvitge Biomedical Research Institute (IDIBELL), created in December 2017, and focused on the development and commercialization of a novel Alzheimer’s disease (AD) early detection technology.

Products and services

Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau. Therefore, our unique value proposition is that our test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next generation sequencing.

Areas of interest for future collaborations

Diagnostics, Drugs development and DNA sequencing platforms (next generation sequencing)